

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

#5

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

APPLICANT

ROSTAMI *et al.*


FILING DATE

08/31/2001

GROUP

(use as many sheets as necessary)

Page 1 of 11



RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

AMINER INITIALS	Cite No.	DOCUMENT NUMBER	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
mca	A	4,793,996	Kennedy, <i>et al.</i>	12/27/1988	
	B	5,217,717	Kennedy, <i>et al.</i>	06/08/1993	
	C	5,338,547	Kennedy, <i>et al.</i>	08/16/1994	
	D	5,616,492	Kennedy, <i>et al.</i>	04/01/1997	
	E	5,618,679	Kennedy, <i>et al.</i>	04/08/1997	
↓	F	5,961,980	Kennedy, <i>et al.</i>	10/05/1999	

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No.	Office	DOCUMENT NUMBER	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1	Atkinson, SJ, Ward, RV, Reynolds, JJ, "Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases," <i>Biochem. J.</i> 288:605-611 (1992)	
↓	2	Bai, X.F., F.D. Shi, J. Zhu, B.G. Xiao, G. Hedlund, and H. Link, "Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions," <i>J. Neuroimmunol.</i> 76:177 (1997).	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Page 2 of 11

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

APPLICANT

ROSTAMI *et al.*

FILING DATE

08/31/2001

GROUP

1654

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mor	3	Bar-Or A, Oliveira EM, Anderson DE, Hafler DA, "Molecular pathogenesis of multiple sclerosis," <i>J. Neuroimmunol.</i> 100:252-259 (1999).	
	4	Bever, CT Jr, Rosenberg, GA, "Matrix metalloproteinases; in multiple sclerosis: targets of therapy or markers of injury?" <i>Neurology</i> 53:1380-1381 (1999).	
	5	Billings PC, "Approaches to studying the target enzymes of anticarcinogenic protease inhibitors," In <i>Protease Inhibitors as Cancer Chemopreventive Agents</i> , Troll W, Kennedy AR (eds.), New York, Plenum Press, 1993, pp. 191-198.	
	6	Billings, PC, Brandon, DL, Habres, JM, "Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells," <i>Eur. J. Canc.</i> 27:903-908 (1991B)	
	7	Billings, PC, Clair, WHS, Maki, PA, Kennedy, AR, "Distribution of the Bowman-Birk inhibitor in mice following oral administration," <i>Canc. Lett.</i> 62:191-197 (1992)	
	8	Billings, PC, Habres, JM, Liao, DC, Tuttle, SW, "Human Fibroblasts Contain a Proteolytic Activity Which Is Inhibited by the Bowman-Birk Protease Inhibitor," <i>Cancer Res.</i> 50:5539-5543 (1991A)	
	9	Birk, Y, "Protease Inhibitors of Plant Origin and the Role of Protease Inhibitors in Human Nutrition," In <i>Protease Inhibitors as Cancer Chemopreventive Agents</i> . Troll W, Kennedy AR (eds). New York, Plenum Press, 1993, pp. 97-106	
	10	Birk, Y, "Proteinase inhibitors from plant sources," <i>Meth. Enzymol.</i> 45:695-751 (1975)	
J	11	Birk, Y, "The Bowman-Birk Inhibitor," <i>J. Peptide Protein Res.</i> 25:113-134 (1985)	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

(use as many sheets as necessary)

APPLICANT


ROSTAMI *et al.*

FILING DATE

08/31/2001

GROUP

Page 3 of 11

1654
RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
ms	12	Boccaccio, GL, Steinman, L, "Multiple sclerosis: from a myelin point of view," <i>J. Neurosci. Res.</i> [volume 45]:647-654 (1996)	
	13	Bowman, DE, "Fractions derived from soybeans and Navy beans which retard tryptic digestion of casein," <i>Proc. Soc. Exp. Biol. Med.</i> 57:139-140 (1944)	
	14	Bowman, DE, "Further identification of bean trypsin inhibiting factors," <i>Arch. Biochem. Biophys.</i> 16:109-113 (1948)	
	15	Brosnan, CR, Caminer, W, Norton, WT, Bloom, BR, "Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis," <i>Nature</i> 285:235-237 (1980).	
	16	Brostoff, SW, Burnett, P, Lampert, PW, Eylar, EH, "Isolation and characterization of a protein from sciatic nerve myelin responsible for experimental allergic neuritis," <i>Nat. New Biol.</i> 235:210-212 (1972)	
	17	Clements, JM, Cossins, JA, Wells, GM, Corkill, DJ, Helfrich, Y, Wood, LM, Pigott, R, Stabler, G, Ward, GA, Gearing, AJ, Miller, KM, "Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor," <i>J. Neuroimmunol.</i> 74:85-94 (1997)	
	18	Constantinescu, C.S., Wysocka, M., Hilliard, B., Venyura, E.S., Lavi, E., Trinchieri, G. and Rostami, A., "Antibodies Against IL-12 Prevent Superantigen-Induced and Spontaneous Relapses of Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 161:5097-5104 (1998)	
↓	19	Constantinescu, CS, Hilliard, B, Fujioka, T, Bhopale, MK, Calida, D, Rostami, AM, "Pathogenesis of Neuroimmunologic Diseases: Experimental Models," <i>Immunologic Res.</i> 17:217-227 (1998)	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

APPLICANT

ROSTAMI *et al.*

FILING DATE

08/31/2001

GROUP

1654


RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

(use as many sheets as necessary)

Page 4 of 11



OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mcj	20	Cuzner ML, Opdenakker G, "Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system," <i>J. Neuroimmunol.</i> 94:1-14 (1999)	
	21	Cuzner, MI, Norton, WT, "Biochemistry of demyelination," <i>Brain Pathol.</i> [volume 6] 231-242 (1996A)	
	22	Dietsch, GN, Hinrichs, DJ, "Mast cell proteases liberate stable encephalitogenic fragments from intact myelin," <i>Cell. Immunol.</i> 135:541-548 (1991)	
	23	Evans <i>et al.</i> , <i>Radiat. Res.</i> 132:259-262 (1992) "Protection against Metastasis of Radiation-Induced Thymic Lymphosarcoma and Weight Loss in C57Bl/6NCr1BR Mice by an Autoclave-Resistant Factor Present in Soybeans".	
	24	Frenkel, K, Chrazan, K, Ryan, CA, Wiesner, R, Troll, W, "Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes," <i>Carcinogenesis</i> 8:1207-1212 (1987)	
	25	Fujioka, T., E. Purev, and A. Rostami, "Chemokine mRNA expression in the cauda equina of Lewis rats with experimental allergic neuritis," <i>J. Neuroimmunol.</i> 97:51 (1999).	
	26	Fujioka, T., T. Jimi, B.A. Hilliard, E.S. Ventura, and A. Rostami, "The expression of cytokine mRNA in the cauda equina of Lewis rats with experimental allergic neuritis," <i>J. Neuroimmunol.</i> 84:223 (1998)	
	27	Gijbels, K, Galardy, RE, Steinman, L, "Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases," <i>J. Clin. Invest.</i> 94:2177-2182 (1994)	
✓	28	Gladysheva, IP, Larionova, NI, Gladyshev, DP, Tikhonova, TV, Kazanskaia, NF, "The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G," <i>Biochemistry (Moscow)</i> 59(4):513-518 (1994)	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

APPLICANT

ROSTAMI *et al.*


FILING DATE

08/31/2001

GROUP

(use as many sheets as necessary)

Page 5 of 11

1654
RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mcj	29	Gold, R., J.J. Archelos, and H.P. Hartung, "Mechanisms of immune regulation in the peripheral nervous system," <i>Brain Pathol.</i> 9: 343 (1999)	
	30	Halonon, T, Kilpelainen, H, Pitkanen, A, Riekkinen, PJ, "Lysosomal hudrolases in cerebrospinal fluid of multiple sclerosis patients," <i>J. Neurol. Sci.</i> 79:267-274 (1987)	
	31	Hartung, HP, Kieseier, BC, "The role of metalloproteinases in autoimmune damage to the central and peripheral nervous system," <i>J. Neuroimmunol.</i> 107:140-147 (2000)	
	32	Hauser, SL, Goodkin, DE, "Multiple Sclerosis and Other Demyelinating Diseases," In <i>Harrison's Principles of Internal Medicine</i> . Fauci <i>et al.</i> (eds). New York, McGraw-Hill, 1998, pp. 2409-2419	
	33	Hawkins, JV, Emmel, EL, Feuer, A, Nedelman, MA, Harvey, CJ, Klein, HJ, Rozmiarek, J, Kennedy, AR, Lichtenstien, GR, Billings, PC, "Protease activity in a hapten-induced model of ulcerative colitis in rats," <i>Digestive Diseases and Sciences</i> 42:1969-1980 (1996)	
	34	Hewson, AY, Smith, T, Leonard, JP, Cuzner, ML, "Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790," <i>Inflamm. Res.</i> 44:345-349 (1995)	
	35	Ibrahim, MZM, Reder, AT, Lawand, R, Takash, W, Sallouh-Khatib, S, "The mast cells of the multiple sclerosis brain," <i>J. Neuroimmunol.</i> 70:131-138 (1996)	
	36	Kennedy, AR, "Anticarcinogenic activity of protease inhibitors: Overview," In <i>Protease-Inhibitors as Cancer Chemopreventive Agents</i> , Troll, W, Kennedy, AR (eds). New York, Plenum Press, 1993A, pp. 9-64	
✓	37	Kennedy, AR, "Cancer prevention by protease inhibitors," <i>Preventive Med.</i> 22:796-811 (1993C)	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
22253-69814SERIAL NO.
09/943,688APPLICANT
ROSTAMI *et al.*FILING DATE
08/31/2001

GROUP

(use as many sheets as necessary)

Page 6 of 11

1654
RECEIVEDJUL 11 2002
TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mcj	38	Kennedy, AR, "Chemopreventive Agents: Protease Inhibitors," <i>Pharmacological Therapeutics</i> 78:167-209 (1998)	
	39	Kennedy, AR, "Mechanisms. of cancer prevention: Effects of protease inhibitors on protease and gene expression," In <i>Nutrients in Cancer Prevention and Treatment</i> , Prasad (ed) 1995B, pp. 71-82	
	40	Kennedy, AR, "Prevention of carcinogenesis by protease inhibitors," <i>Cancer Res. (suppl)</i> 54:1999s-2005s (1994)	
	41	Kennedy, AR, "The evidence for soybean products as cancer preventive agents," <i>J. Nutr.</i> 125:733s-743s (1995C)	
	42	Kennedy, AR, Letter to the editor, <i>J. Nutr.</i> 126:584-585 (1996)	
	43	Kennedy, AR, Little, JB, "Protease, inhibitors suppress radiation induced malignant transformation <i>in vitro</i> ," <i>Nature</i> 276:825-826 (1978)	
	44	Kennedy, AR, Manzone, H, "Effects of protease inhibitors on levels of proteolytic activity in normal and pre-malignant cells and tissues," <i>J. Cell. Biochem.</i> 22:188-194 (1995A)	
	45	Kennedy, AR, Szuhaj, BF, Newberne, PM, Billings, PC, "Preparation and production of a cancer chemopreventive agent, Bowman-Birk Inhibitor Concentrate," <i>Nutr. Cancer</i> 19:281-302 (1993B)	
	46	Kieseier, BC, Storch, MK, Archelos, JJ, Martino, G, Hartung, HP, "Effector pathways in immune mediated central nervous system demyelination," <i>Curr. Opin. Neurol.</i> 12:323-336 (1999)	
✓	47	Kremlev, S.G., A.I. Chapoval, and R. Evans, "Cytokine release by macrophages after interacting with CSF-1 and extracellular matrix proteins: characteristics of a mouse model of inflammatory responses <i>in vitro</i> ," <i>Cell. Immunol.</i> 185:59 (1998)	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

(use as many sheets as necessary)

APPLICANT


ROSTAMI *et al.*

FILING DATE

08/31/2001

GROUP

Page 7 of 11

1654
RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mc2	48	Larionova, NI, Gladysheva, IP, Tikhonova, TV, Kazanskaia, NF, "Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor," <i>Biochemistry</i> (Moscow) 58:1437-44 (1993)	
	49	Maeda, A, Sobel, RA, "Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions," <i>J. Neuropathol. Experimental Neurol.</i> 55:300-309 (1996)	
	50	Maki, <i>et al.</i> , "Studies Related to the Potential Antigenicity of the Bowman-Birk Inhibitor, an Anticarcinogenic Protease Inhibitor Isolated From Soybeans", <i>Nutr. Cancer</i> 22:185-193 (1994).	
	51	Malkowicz, SB, McKenna, W.G., Vaughn, DJ, Wan, XS, Probert, KJ, Rockwell, K, Marks, SHF, Wein, AJ, Kennedy, AR, "Effects of Bowman-Birk Inhibitor Concentrate in patients with benign prostatic hyperplasia," <i>The Prostate</i> 48:16-28 (2001)	
	52	Meyskens, FL, Armstrong, WB, Wan, XS, Taylor, TH, Jenson, J, Thompson, W, Nguyen, QA, Kennedy, AR, "Bowman-Birk inhibitor concentrate (BBIC) affects oral leukoplakia lesion size, neu protein levels and proteolytic activity in buccal mucosal cells," <i>Proc. Amer. Assoc. Cancer Res.</i> 40:Abstract #2855 (1999)	
	53	Murphy, G, Atkinson, S, Ward, R, "The role of plasminogen activators in the regulation of connective tissue metalloproteinases," <i>Ann. N.Y. Acad. Sci.</i> 667:1-12 (1992)	
	54	Odani, S, Ikenaka, T, "Studies on soybean trypsin inhibitors VII. Disulfide bridges in soybean Bowman-Birk proteinase inhibitor," <i>J. Biochem.</i> 74:697-715 (1973)	
	55	Opdenakker, G, Van Damme, J, "Cytokine-regulated proteases in autoimmune diseases," <i>Immunol. Today</i> 15:103-107 (1994)	
✓	56	Owens, T., T. Renno, V. Taupin, and M. Krakowski, "Inflammatory cytokines in the brain: does the CNS shape immune responses?" <i>Immunol. Today.</i> 15:566 (1994)	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

ATTY. DOCKET NO.
22253-69814

SERIAL NO.
09/943,688


(use as many sheets as necessary)

APPLICANT
ROSTAMI *et al.*

FILING DATE
08/31/2001

GROUP

Page 8 of 11



16534
RECEIVED
JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mcj	57	Page, JG, Heath, JE, May, RD, and Martin, JF, "13-week toxicity study of Bowman Birk Inhibitor Concentrate (BBIC) in rats," SRI-CBE-94-060-7482, Southern Research Institute, Birmingham, AL (1994)	
	58	Page, JG, Rodman, LE, Giles, HD, Farnell, DR and Wood, RD, "13-week toxicity study of Bowman Birk Inhibitor Concentrate (BBIC) in dogs," SRI-CBE-94-135-7482, Southern Research Institute, Birmingham, AL (1994)	
	59	Raine CS, "The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion," <i>Ann. Neurol.</i> 36:S61-72 (1994)	
	60	Raine, CS, "Demyelinating Diseases," In <i>Textbook of Neuropathology</i> . Davis RL (ed) Baltimore, MD, Williams and Wilkins, 1990, pp. 356-358	
	61	Rivers, TM, Sprunt, DH, Berry, GP, "Observations on attempts to produce acute disseminated encephalomyelitis in monkeys," <i>J. Exp. Med.</i> 58:39-53 (1933)	
	62	Romanic, AM, Madri, JA, "Extracellular matrix-degrading proteinases in the nervous system," <i>Brain Pathol.</i> 4:145-156 (1994)	
	63	Rosen, J.L., M. Brown, and A. Rostami, "Evolution of the cellular response in P2-induced experimental allergic neuritis," <i>Pathobiology</i> 60:108 (1992)	
	64	Rosen, JL, Brown, MJ, Hickey, WF, Rostami, AM, "Early myelin lesions in experimental allergic neuritis," <i>Muscle and Nerve</i> 13:629-636 (1990)	
✓	65	Rostami, AM, "Guillain-Barre syndrome: clinical and immunological aspects," <i>Springer Semin. Immunopathol.</i> 17:29-42 (1995)	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

APPLICANT

ROSTAMI *et al.*

FILING DATE


08/31/2001

GROUP

1655

(use as many sheets as necessary)

Page 9 of 11



OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mcj	66	Rostami, AM, Brown, MJ, Lisak, RP, Sumner, AJ, Zweiman, B, Pleasure, DE, "The role of Myelin P2 protein in the production of experimental allergic neuritis," <i>Ann. Neurol.</i> 16:680-685 (1984)	
	67	Rostami, AM, Gregorian, SK, Brown, MJ, Pleasure, DE, "Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein," <i>J. Neuroimmunol.</i> 30:145-151 (1990)	
	68	Serota, DG, "One-year oral toxicity study of Bowman Birk Inhibitor Concentrate in Dogs., 560-058, MPI Research, Inc., Mattawan, MI (2000)	
	69	Serota, DG, "Six-month oral toxicity study of Bowman-Birk Inhibitor Concentrate in mice," 560-057, MPI Research, Inc., Mattawan, MI (2000)	
	70	Shang, X.Z., B.J. Lang, and A.C. Issekutz, "Adhesion molecule mechanisms mediating monocyte migration through synovial fibroblast and endothelium barriers: role for CD11/CD18, very late antigen-4 (CD49d/CD29), very late antigen-5 (CD49e/CD29), and vascular cell adhesion molecule-1 (CD106)," <i>J. Immunol.</i> 160:467 (1998)	
	71	St. Clair <i>et al.</i> , "Suppression of Dimethylhydrazine-induced Carcinogenesis in Mice by Dietary Addition of the Bowman-Birk Protease Inhibitor", <i>Cancer Res.</i> 50:580-586 (1990)	
	72	Tikhonova, TV, Gladysheva, IEP, Kazanshaya, NF, Larionova NI, "Hydrolysis of elastin by human leukocyte elastase and cathepsin G: Inhibition by Bowman Birk type inhibitor," <i>Biochemistry (Moscow)</i> 59:1295-1299 (1994)	
✓	73	Vaday GG, Lider O, "Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation," <i>J. Leukoc. Biol.</i> 67:149-159 (Feb., 2000)	

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY: DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

(use as many sheets as necessary)

APPLICANT


ROSTAMI *et al.*

FILING DATE

08/31/2001

GROUP

Page 10 of 11

1653 K-5
RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mcg	74	Vaddi K- and R.C. Newton, "Regulation of monocyte integrin expression by Beta-family chemokines," <i>J. Immunol.</i> 153:4721 (1994)	
	75	van Hofe <i>et al.</i> , "Inhibition of N-nitrosomethylbenzylamine-induced esophageal neoplasms by the Bowman-Birk protease inhibitor", <i>Carcinogenesis</i> 12:2147-2150 (1991)	
	76	Waksman, BH, Adams, RD, "Allergic neuritis? An experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants," <i>J. Exp. Med.</i> 102:213-236 (1955)	
	77	Wan <i>et al.</i> , "Relationship between Protease Activity and <i>neu</i> Oncogene Expression in Patients with Oral Leukoplakia Treated with the Bowman Birk Inhibitor", <i>Cancer Epidem. Biomarkers & Prevention</i> 8:601-608 (1999)	
	78	Wan, XS, Koch, CJ, Lord, EM, Manzone, H, Billings, PC, Donahue, JJ, Odell, C, Miller, JH, Schmidt, NA, Kennedy, AR, "Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor," <i>J. Immunol. Meth.</i> 180:117-130 (1995)	
	79	Ware, JH, Wan, XS, Kennedy, AR, "The Bowman-Birk Inhibitor Suppresses Production of Superoxide Anion Radicals in Differentiated HL-60 Cells," <i>Cancer and Nutrition</i> 33:174-177 (1999)	
	80	Ware, JH, Wan, XS, Newberne, P, Kennedy, AR, "Bowman-Birk Inhibitor Concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis," <i>Digestive Diseases and Sciences</i> 44:896-90 (1999)	
✓	81	Ware, JH, Wan, XS, Rubin, H, Schechter, NM, Kennedy, AR, "Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase," <i>Arch. Biochem. Biophys.</i> 344:133-138 (1997)	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

ATTY. DOCKET NO.

22253-69814

SERIAL NO.

09/943,688

APPLICANT

ROSTAMI *et al.*


FILING DATE

08/31/2001

GROUP

(use as many sheets as necessary)

Page 11 of 11

1654 1654
RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book; magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
mc7	82	Weber, C., R. Alon, B. Moser, and T.A. Springer, "Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis," <i>J Cell. Biol.</i> 134:1063 (1996)	
	83	Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L, Warren KG, "Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes," <i>J. Clin. Invest.</i> 100(5):1114-1122 (1997)	
	84	Yavelow, J, Collins, M, Birk, Y, Troll, W, Kennedy, AR, "Nanomolar concentrations of Bowman-Birk soybean protease inhibitors suppress X-ray induced transformation in vitro," <i>Proc. Nat'l. Acad. Sci. USA</i> 82:5395-5399 (1985)	
✓	85	Yavelow, J, Finlay, TH, Kennedy, AR, Troll, W, "Bowman-Birk soybean protease inhibitor as an anticarcinogen," <i>Cancer Res.</i> 43:2454-2459 (1983)	

Michelle C. Flood 9/2/2003



OCTOBER 07, 2002

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

DILWORTH PAXSON LLP
EVELYN H. MCCONATHY, ESQ.
3200 MELLON BANK CENTER
1735 MARKET STREET
PHILADELPHIA, PENNSYLVANIA 19130



102180766A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/05/2002

REEL/FRAME: 013149/0260
NUMBER OF PAGES: 4

BRIEF: DOCUMENT PREVIOUSLY RECORDED AT REEL 012652 FRAME 0346 CONTAINED ERRORS IN PATENT APPLICATION NUMBER 09/909382. DOCUMENT RERECORDED TO CORRECT ERROS ON STATED REEL.

ASSIGNOR:

ROSTAMI, ABDOLMOHAMAD

DOC DATE: 02/26/2002

ASSIGNOR:

KENNEDY, ANN R.

DOC DATE: 02/26/2002

ASSIGNEE:

TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA, THE
3160 CHESTNUT STREET, SUITE 200
PHILADELPHIA, PENNSYLVANIA 19104

SERIAL NUMBER: 09943688
PATENT NUMBER:

FILING DATE: 08/31/2001
ISSUE DATE:

FOR FILE <u>2253-69814US</u>
OCT 14 2002
DILWORTH PAXSON LLP ATTN: <u>N-2380</u>

013149/0260 PAGE 2

ALLYSON PURNELL, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

08-07-2002

Form PTO-1595

(Rev. 03/01)

OMB No. 0651-0027 (exp. 5/31/2002)



102180766

ET

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Attorney Docket No. 69814 (N2380)

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof:

1. Name of conveying parties:

Abdolmohamad ROSTAMI
Ann R. KENNEDYARD
8-5-02

2. Name and address of receiving party(ies):

Name: The Trustees of the University of Pennsylvania

Street Address: at 3160 Chestnut Street, Suite 200

City: Philadelphia State: Pennsylvania Zip: 19104

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of Conveyance:

☐ Assignment☐ Merger☐ Security Agreement☐ Change of Name☒ Other: **Correction of Assignment Recordation**

(Reel/Frame 012652/0346 to be corrected (original Notice of Recordation attached hereto) - incorrect Application No. cited in original filing)

Additional name(s) and address(es) attached? ☐ Yes ☒ No

Execution date(s): 02/26/2002

4. Application number(s) or patent number(s):

A. Patent Application No.(s): 09/943,688

B. Patent No.(s):

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Evelyn H. McConathy, Esquire
DILWORTH PAXSON LLP
3200 Mellon Bank Center
1735 Market Street
Philadelphia, PA 191306. Total number of applications and patents involved: 17. Total fee (37 CFR 3.41) \$40.00☒ Enclosed☐ Authorized to be charged to deposit account8. Deposit Account No. 50-0979

DO NOT USE THIS SPACE

9. Signature

Evelyn H. McConathy, Reg. No 35,279

Name of Person Signing/Registration No.

Evelyn H. McConathy
Signature

July 29, 2002

Date

Total number of pages including cover sheet, attachments and documents: 6


08/06/2002 T0IAZ1 00000172 09943688

01 FC:581

40.00 CP

459936 1

OFFICE OF PUBLIC RECORDS
2002 AUG -5 AM 11:54
FINANCE SECTION


**RECORDATION FORM COVER SHEET
PATENTS ONLY**

To The Commissioner of Patents and Trademarks: Please record the attached original document and a copy thereof.

<p>1. Name of Conveying Party(ies)</p> <p>Abdolmohamad Rostami Ann R. Kennedy</p> <p>Additional name(s) of Conveying Parties attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and Address of Receiving Party(ies):</p> <p>THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Center for Technology Transfer 3700 Market Street—Suite 300 Philadelphia, Pennsylvania 19104-3147</p> <p>Additional name(s) and address(es) of Receiving Parties</p>
--	--

3. SUBMISSION TYPE**CONVEYANCE TYPE**☒ NEW☒ Assignment☐ Resubmission (NON-RECORDATION) Document ID# _____☐ License☐ Correction of PTO Error (Reel ____/Frame ____)☐ Merger☐ Corrective Document (Reel ____/Frame ____)☐ Security Agreement Execution☐ Change of Name

Execution Date(s): February 26, 2002

☐ Other:

4. Application number(s) or patent number(s).

Additional numbers attached? No

If this document is being filed together with a new application,
enter the date the patent application was signed by the first named inventor: 02/26/2002

A. Patent Application No.(s):

09/909,382

B. Patent No.(s):

5. Name and address of party to whom correspondence concerning documents should be mailed:

Evelyn H. McConathy, Esquire
DILWORTH PAXSON LLP
3200 Mellon Bank Center
1735 Market Street
Philadelphia, PA 19103-7595

6. Number of applications and patents involved: 17. Total Fee (37 C.F.R. §3.41): \$40.00Enclosed: \$40.00

Authorized to be Charged: \$ _____

8. Deposit account number: 50-0979

(Attach duplicate copy of this form if paying by deposit account.)

DO NOT USE THIS SPACE

9. To the best of knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Date: March 4, 2002

Evelyn H. McConathy
Evelyn H. McConathy, Reg. No. 35,279

Total number of pages including cover sheet, attachments and documents: 3

03/08/2002 NMOHAMM1 00000025 09943688

03 FC:581

CLIENT REP. N-2380

40.00 0P

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to the undersigned INVENTOR(S) (the Assignors), the undersigned hereby sell and assign their entire right, title and interest to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (the Assignee), a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania having its principal place of business at 3700 Market Street, Suite 300, Philadelphia, Pennsylvania 19104-3147 for

in the invention known as USE OF BOWMAN BIRK INHIBITOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES, filed August 31, 2001 (also known as U.S. Application Serial No. 09/943,688 in any and all applications thereon, in any and all Letters Patent(s) therefor, and in any and all reissues, extensions, renewals, reexaminations of such applications or Letters Patent(s) and divisionals and continuing applications thereof to the full end of the term or terms for which such Letters Patent(s) issue, such entire right, title and interest to be held and enjoyed by the above-named Assignee to the same extent as they would have been held and enjoyed by the undersigned had this assignment and sale not been made.

The undersigned agree to execute all papers necessary in connection with any interference that may be declared concerning the application or any continuing, divisional, reissue or reexamination applications thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference.

394099-1

IN WITNESS WHEREOF, executed by the undersigned on the dates opposite their names.

Date: 2/26/02


Signature of Inventor: 

ABDOLMOHAMAD ROSTAMI

Commonwealth of Pennsylvania:

COUNTY of Philadelphia SS

On this 26 day of February 2002, before me personally came the above ABDOLMOHAMAD ROSTAMI, to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that he executed the same of his own free will for the use and purposes therein set forth.



Date: February 26, 2002

Signature of Inventor: 


ANN R. KENNEDY

Commonwealth of Pennsylvania:

COUNTY of Philadelphia SS

On this 26 day of February 2002, before me personally came the above ANN R. KENNEDY, to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that he executed the same of her own free will for the use and purposes therein set forth.


Notary Public





MAY 03, 2002

PTAS

Commissioner for Trademarks
Arlington, VA 22202-3513
www.uspto.gov

DILWORTH PAXSON LLP
EVELYN H. MCCONATHY, ESQ
3200 MELLON BANK CENTER
1735 MARKET STREET
PHILADELPHIA, PA 19103-7595



102013987A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 03/04/2002

REEL/FRAME: 012652/0346
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ROSTAMI, ABDOLMOHAMAD

DOC DATE: 02/26/2002

ASSIGNOR:

KENNEDY, ANN R.

DOC DATE: 02/26/2002

ASSIGNEE:

TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA, THE
CENTER FOR TECHNOLOGY TRANSFER
3700 MARKET STREET-SUITE 300
PHILADELPHIA, PENNSYLVANIA

19104-3147

SERIAL NUMBER: 09909382
PATENT NUMBER:

FILING DATE: 07/20/2001
ISSUE DATE:

DOCKETED

lm

FILE	FOR 22253-164817
MAY 13 2002	
DILWORTH PAXSON LLP	
ATTN:	

012652/0346 PAGE 2

SEDLEY PYNE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS